Trial Profile
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jan 2024
Price :
$35
*
At a glance
- Drugs Surzebiclimab (Primary) ; Tislelizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 09 Nov 2022 According to a BeiGene media release, initiated patient dosing of this study.
- 26 Aug 2022 Arm Phase 2 Safety Lead-in added and primary endpoint for Phase 2 Safety Lead-in added newly.
- 26 Aug 2022 Planned number of patients changed from 162 to 358.